Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
|Podcasts|August 18, 2022
Pharmacy Focus: Independent Rx Forum- NCPA's Student Business Plan Competition
Each year, the NCPA Annual Convention is able to showcase student business plans in a competition that correlates to a real life business plan.
Advertisement
Today's episode features Jack Mozloom and guests Carlie Traylor and Whitney Brace who discuss what to expect at the upcoming Student Business Plan Competition at the NCPA Annual Convention.
Advertisement
Related to this article
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Target Trial Emulation Finds Limited Survival Benefit With Statins After Colorectal Cancer Treatment
Statin initiation after colorectal cancer treatment was associated with only modest survival differences after investigators accounted for biases that can exaggerate benefits in observational research.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Data Reshapes Nonstatin Lipid Therapy Choices
2
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Medication Management: A Crucial Part of Healthy Aging
5